TY - T1的血清和CSF中枢神经系统莱姆病患者细胞因子活跃,其他中枢神经系统炎症性疾病、脑病莱姆病治疗后,其他脑病,神经学和正常对照组(S37.007) JF -乔-神经学六世- 84 - 14补充SP S37.007 AU -约翰·霍尔柏林盟哈维尔Pacheco-Quinto AU -艾梅•盟负责人Elizabeth a Eckman Y1 - 2015/04/06 UR - //www.ez-admanager.com/cont首页ent/84/14_Supplement/S37.007.abstract N2 -目的:探讨假设神经行为发生在一些莱姆病患者治疗后症状不是由于中枢神经系统感染/炎症,但可能系统性炎症。背景:莱姆病患者治疗后症状的病因是未知的和神经行为的症状往往不准确归因于中枢神经系统感染。尽管缺乏证据,有症状的患者经常收到重复疗程的抗生素,这是无效的。在缺乏持续的感染,这些症状可能会从一个异常的免疫反应。设计/方法:使用多路复用化验,我们从患者血清中炎症概要特征后处理症状包括头痛、脑病(n = 64)。结果相比从患者相似的症状与莱姆病(n = 47)无关,活跃的患者中枢神经系统感染(n = 15),与健康对照组(n = 50)。类似的分析进行了脑脊液从这些患者的一个子集,和额外的non-Lyme神经炎症患者。结果:脑脊液脑脊液细胞增多和海拔在多种细胞因子和趋化因子,包括CXCL13、活跃的患者被发现中枢神经系统莱姆病感染和其他神经炎症条件,但不是在治疗后患者的症状。在血清,IL-7水平明显升高患者的神经行为症状治疗后莱姆病(4.24±0.83 pg / ml 0.70±0.07 pg / ml相比控制)。IL-7同样升高在有症状的患者没有莱姆病的历史。 Compared to controls, symptomatic patients also had higher levels of IL-17A, IL-17F, and MIP-1alpha. Conclusions: Patients with neurobehavioral symptoms following treatment for Lyme disease do not show any evidence of nervous system infection or inflammation. Elevations in serum IL-7 and IL-17 in these patients may reflect T-cell dysregulation. Interestingly, such elevations were seen in symptomatic patients regardless of prior Lyme disease exposure. These results warrant further investigation, as IL-7 may represent a useful biomarker, and could lead to the identification of novel therapeutic targets.Disclosure: Dr. Halperin has received personal compensation in an editorial capacity for The Neurologist. Dr. Halperin holds stock and/or stock options in Abbott Labs, Bristol Myers Squib, Johnson & Johnson. Dr. Pacheco-Quinto has nothing to disclose. Dr. Herdt has nothing to disclose. Dr. Eckman has nothing to disclose.Wednesday, April 22 2015, 4:00 pm-5:45 pm ER -